Matinas Biopharma Holdings Inc. (MTNB)
NYSE · Healthcare
Matinas Biopharma Holdings Inc. EBITDA 2014–2023
Matinas Biopharma Holdings Inc. annual/quarterly ebitda history and growth rate from 2014 to 2023. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Matinas Biopharma Holdings Inc. ebitda for the quarter ending March 31, 2023 was -5.5 M, a 12.73% decrease year-over-year.
- Matinas Biopharma Holdings Inc. ebitda for the twelve months ending March 31, 2023 was -23.0 M, a 44.74% increase year-over-year.
- Matinas Biopharma Holdings Inc. annual ebitda for 2023 was -23.4 M, a 3.60% decrease from 2022.
- Matinas Biopharma Holdings Inc. annual ebitda for 2022 was -24.3 M, a 0.97% decrease from 2021.
- Matinas Biopharma Holdings Inc. annual ebitda for 2021 was -24.5 M, a 2.15% increase from 2020.
- Matinas Biopharma Holdings Inc. annual ebitda for 2020 was -24.0 M.
EBITDA
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Matinas Biopharma Holdings Inc. EBITDA — FAQ
Matinas Biopharma Holdings Inc. (MTNB) ebitda over the last 10 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see MTNB's ebitda history?
The chart and table above show Matinas Biopharma Holdings Inc.'s ebitda by year and by quarter, including the growth rate.